

AcrySof® IQ PanOptix® Trifocal Intraocular Lens

with ENLIGHTEN™ Optical Technology:
Addressing the full range of vision needs for cataract patients



The PanOptix® Lens is clinically shown to deliver an exceptional combination of near, intermediate, and distance vision to patients while significantly reducing the need for glasses after cataract surgery.

PanOptix® is a revolutionary trifocal IOL for patients undergoing cataract surgery at Maryland Vision Institute.



It is the first and only trifocal lens approved by the U.S. Food and Drug Administration (FDA) and available in the U.S.



20/20 near, intermediate and distance vision is now possible with PanOptix®

* Based on mean value of binocular defocus from curve at near, intermediate and distance at 6 months. Snellen VA was converted from logMAR VA. A Snellen notation of 20/20² or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 ETDRS chart letters in the line were identified correctly.

120 M

PanOptix® is built on Alcon's proven AcrySof IQ IOL platform that has been implanted in more than 120 million eyes globally.

Clinically-Proven Benefits

The FDA approval of PanOptix® was based on a pivotal study at 12 investigational sites in the U.S. With this single trifocal lens design, PanOptix® patients demonstrated exceptional, uninterrupted vision.

Results from the 129 subjects implanted with PanOptix® in the prospective and parallel-group clinical study revealed that:

99

More than 99% of PanOptix® patients in the FDA clinical study said they would choose the same lens again.

98

98% of PanOptix® patients would recommend the PanOptix® IOL to their friends and family.


80.5

80.5% of PanOptix® patients reported in a survey that they never needed to wear glasses after surgery.

How Does PanOptix® Work?

ENLIGHTEN™

ENhanced LIGHT ENergy



PanOptix® utilizes Alcon's proprietary, non-apodized ENLIGHTEN (ENhanced LIGHT ENergy) Optical Technology, which optimizes intermediate vision without compromising on near and distance.

Alcon created this patented technology as a solution to improve on the limitations of traditional trifocal IOLs, which typically have an intermediate focal point that isn't comfortable for most patients.

PanOptix® offers an excellent intermediate vision range and is designed to improve vision after cataract surgery for today's active lifestyles, from viewing mobile devices to high-quality distance vision in a range of lighting conditions.

4M

Did you know? More than 4 million cataract surgeries are performed each year in the U.S., a number that is projected to increase by more than 16 percent by the end of 2024.



Sidney Chang, M.D.

Gus Stern, M.D.

“After performing cataract surgery for years, Dr. Chang and I understand that patients want the type of vision after cataract surgery that enables them to live full, active lives without always being dependent on glasses. The PanOptix® Intraocular Lens allows us to deliver that quality of vision to our patients.”

Maryland Vision Institute